HRS-4729
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 16, 2025
Hengrui Class 1 innovative drug GLP-1R/GIPR/GCGR tri-receptor agonist HRS-4729 for metabolic-associated fatty liver disease/metabolic-related steatohepatitis approved clinical [Google translation]
(Jiangsu Hengrui Press Release)
New trial • Metabolic Dysfunction-Associated Steatohepatitis
1 to 1
Of
1
Go to page
1